… treatment option for patients with multiple myeloma, offering significant improvements in progression … for patients with newly diagnosed multiple myeloma who are ineligible for … of care for transplant-ineligible multiple myeloma patients [across the UK]” …

… adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem … this mission. Now, patients with multiple myeloma and their providers have access …

… adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem … this mission. Now, patients with multiple myeloma and their providers have access …

… observed among patients [with multiple myeloma], where it correlates with … [patients with] CHIP-carrying [multiple myeloma], particularly regarding therapy-related toxicity … frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter …

… with relapsed/ refractory multiple myeloma: idecabtagene vicleucel (ide-cel; … in transplant-eligible newly diagnosed multiple myeloma (NDMM): CASSIOPEIA minimal … posttransplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023; …

… patients with relapsed/refractory multiple myeloma. In the retrospective real-world … , patients with relapsed/refractory multiple myeloma outside of a clinical trial …

… of the Multiple Myeloma Research Foundation (MMRF), discussed challenges in multiple myeloma clinical trials … helping biopharma companies evaluate their multiple myeloma therapies in trials they wouldn …

… treat adults with newly diagnosed multiple myeloma (NDMM) who are not eligible … this mission. Now patients with multiple myeloma and their providers have access …

… treatment options for patients with multiple myeloma. Pomalikin is available in four …

… with relapsed/refractory multiple myeloma and baseline renal impairment, … Patients with [relapsed/refractory multiple myeloma] and baseline [renal impairment] exhibited … with [relapsed/refractory multiple myeloma] and baseline [renal impairment]. …